News | July 19, 2023
SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Moist wound dressing for chronic wound treatment now available in Germany
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Cipla has a robust governance model focused on sustainability
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
